Enveric Biosciences, Inc. (ENVB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Enveric Biosciences, Inc. (ENVB) trades at $1.47 with AI Score 31/100 (Grade D). Enveric Biosciences, Inc. is a pharmaceutical company focused on developing cannabinoid medicines for cancer care. Market cap: $877,608, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for ENVB: ENVB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENVB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ENVB: 1/1 perspectives are bearish.
How is this calculated? →Enveric Biosciences, Inc. (ENVB) Healthcare & Pipeline Overview
Enveric Biosciences, Inc. is a biotechnology company developing cannabinoid-based therapeutics for cancer care and related conditions. Its pipeline focuses on innovative treatments for osteoarthritis, cancer-related distress, mental health indications, and topical skin applications, positioning it within the evolving pharmaceutical landscape.
What Is the Investment Thesis for ENVB?
Enveric Biosciences presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on cannabinoid-based therapeutics for cancer care and related conditions positions it in a rapidly evolving market. Key value drivers include the successful development and commercialization of its pipeline products, particularly EV104, EVM-101, EVM-201, EVM-301, EV102, and EV101. Growth catalysts include positive clinical trial results, regulatory approvals, and strategic partnerships. However, the company faces significant risks, including the uncertainty of clinical trial outcomes, regulatory hurdles, and competition from established pharmaceutical companies. With a market capitalization of 878K and a P/E ratio of -0.06, Enveric's valuation is highly dependent on its ability to advance its pipeline and secure funding. Investors should carefully consider the risks and potential rewards associated with this early-stage biotechnology company.
Based on FMP financials and quantitative analysis
ENVB Key Highlights
- Enveric Biosciences is focused on developing cannabinoid medicines for cancer care.
- The company's product pipeline includes EV104 for osteoarthritis and EVM-101 and EVM-201 for cancer-related distress.
- EVM-301 is being developed for mental health indications.
- EV102 is a cannabinoid cream for topical skin application.
- EV101 is a cannabinoid and chemotherapy combination therapy.
Who Are ENVB's Competitors?
ENVB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JSPR Jasper Therapeutics, Inc. | $0.48 | +10.97% | $7.72M | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENVB's Key Strengths?
- Proprietary cannabinoid-based drug development platform.
- Diverse pipeline of therapeutic candidates targeting multiple indications.
- Experienced management team with expertise in drug development.
- Focus on unmet needs in cancer care and related conditions.
What Are ENVB's Weaknesses?
- Limited financial resources and reliance on external funding.
- Early-stage development and high clinical trial risk.
- Small number of employees.
- Dependence on regulatory approvals for commercialization.
What Could Drive ENVB Stock Higher?
- Announcement of clinical trial results for EV104 in osteoarthritis.
- Regulatory submissions for EVM-101 and EVM-201 for cancer-related distress.
- Progress in the development of EVM-301 for mental health indications.
- Expansion of strategic partnerships and collaborations.
- Advancements in the development of novel cannabinoid formulations.
What Are the Key Risks for ENVB?
- Financial-distress signal — its Altman Z-Score of -32.25 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain positive clinical trial results.
- Regulatory delays or rejection of product approvals.
- Competition from established pharmaceutical companies.
- Dependence on external funding and potential dilution of shareholder value.
- Negative perception of cannabinoid-based therapies.
What Are the Growth Opportunities for ENVB?
- Expansion into New Therapeutic Areas: Enveric Biosciences has the opportunity to expand its pipeline beyond cancer care to address other therapeutic areas where cannabinoids may have potential benefits. This could include neurological disorders, autoimmune diseases, and inflammatory conditions. The market for these indications is substantial, with a global market size estimated at billions of dollars. Successful expansion would require additional research and development efforts, as well as strategic partnerships with experts in these fields. Timeline: 2-5 years.
- Strategic Partnerships and Collaborations: Enveric can accelerate its growth by forming strategic partnerships with other pharmaceutical companies, research institutions, and healthcare providers. These collaborations can provide access to new technologies, funding, and market expertise. For example, partnering with a company specializing in drug delivery systems could enhance the bioavailability and efficacy of Enveric's cannabinoid-based therapies. Timeline: Ongoing.
- Advancement of Clinical Trials: The successful advancement of Enveric's pipeline products through clinical trials is crucial for its growth. Positive clinical trial results can lead to regulatory approvals and commercialization, generating significant revenue streams. The company should prioritize its most promising drug candidates and allocate resources to expedite their development. Timeline: Ongoing.
- Geographic Expansion: Enveric has the opportunity to expand its geographic reach beyond the United States to international markets. This could involve establishing partnerships with local distributors or setting up its own operations in key regions. The global market for cannabinoid-based therapeutics is growing rapidly, particularly in Europe and Asia. Timeline: 3-5 years.
- Development of Novel Formulations and Delivery Systems: Enveric can differentiate its products by developing novel formulations and delivery systems that improve their efficacy and patient convenience. This could include developing sustained-release formulations, transdermal patches, or inhaled formulations. The market for innovative drug delivery systems is substantial, with a global market size estimated at billions of dollars. Timeline: 2-4 years.
What Opportunities Does ENVB Have?
- Expansion into new therapeutic areas and geographic markets.
- Strategic partnerships and collaborations with other companies.
- Advancement of clinical trials and regulatory approvals.
- Growing market for cannabinoid-based therapeutics.
What Threats Does ENVB Face?
- Competition from established pharmaceutical companies.
- Uncertainty of clinical trial outcomes.
- Regulatory hurdles and changing regulations.
- Potential negative perception of cannabinoid-based therapies.
What Are ENVB's Competitive Advantages?
- Proprietary cannabinoid formulations and drug delivery systems.
- Intellectual property protection through patents and trademarks.
- Expertise in cannabinoid science and drug development.
- Established relationships with researchers and healthcare providers.
What Does ENVB Do?
Enveric Biosciences, Inc., headquartered in Naples, Florida, is a pharmaceutical company dedicated to the development of cannabinoid-based medicines, primarily targeting cancer care and related conditions. The company's mission is centered around creating innovative therapies that address unmet needs in areas such as pain management, mental health, and dermatological conditions. Enveric's product pipeline includes a range of drug candidates, each designed to leverage the therapeutic potential of cannabinoids. These include EV104 for the treatment of osteoarthritis, EVM-101 and EVM-201 for cancer-related distress, EVM-301 for mental health indications, EV102 as a cannabinoid cream for topical skin application, and EV101, a cannabinoid and chemotherapy combination therapy. Founded with the vision of transforming cancer care through cannabinoid science, Enveric Biosciences has strategically built a pipeline of diverse therapeutic candidates. The company is focused on rigorous research and development to advance its products through clinical trials and regulatory approval. Enveric's approach involves combining cannabinoids with other therapeutic agents to enhance efficacy and address specific disease mechanisms. The company aims to establish itself as a leader in the cannabinoid-based pharmaceutical space, offering innovative solutions for patients and healthcare providers.
What Products and Services Does ENVB Offer?
- Develop cannabinoid medicines for cancer care.
- Research and develop treatments for osteoarthritis.
- Create therapies for cancer-related distress.
- Develop medications for mental health indications.
- Formulate cannabinoid creams for topical skin applications.
- Combine cannabinoids with chemotherapy for enhanced cancer treatment.
How Does ENVB Make Money?
- Develop and patent novel cannabinoid-based therapies.
- Conduct preclinical and clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Commercialize approved products through partnerships or direct sales.
What Industry Does ENVB Operate In?
Enveric Biosciences operates within the biotechnology industry, which is characterized by rapid innovation, high regulatory scrutiny, and significant investment in research and development. The market for cannabinoid-based therapeutics is growing as research reveals the potential therapeutic benefits of cannabinoids for various conditions, including pain, anxiety, and neurological disorders. Enveric competes with other biotechnology and pharmaceutical companies developing similar therapies, as well as established players in the pain management and mental health markets. The company's success depends on its ability to differentiate its products, navigate the regulatory landscape, and secure funding for clinical trials and commercialization.
Who Are ENVB's Key Customers?
- Patients suffering from cancer and related conditions.
- Individuals with osteoarthritis.
- Patients experiencing cancer-related distress.
- Individuals with mental health disorders.
- Patients with skin conditions requiring topical treatment.
Net buyingInsider Activity
The most recent 12 insider filings for Enveric Biosciences, Inc. break down as 0 sales and 12 purchases. On net that is roughly 412K shares acquired (about $0) — insiders putting money in tends to read as conviction.
F-Score 2/9Financial Health
Enveric Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -32.25 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Enveric Biosciences, Inc. revenue of about $10.0M for fiscal 2026, with EPS near $-315.00.
ENVB Valuation & Market Position
With a 878K market cap, Enveric Biosciences, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ENVB's quantitative score of 31/100 is below the peer average of 78/100.
ENVB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Enveric's recent strategic shift towards mental health treatments is gaining traction within the community, signaling a potential growth area.
- Insider buying activity suggests confidence in the company's long-term prospects, despite the inherent risks in biotech.
- The community is buzzing about potential partnerships and collaborations, indicating growing industry interest.
- There's a strong belief that Enveric's unique approach to cannabinoid-based therapies could disrupt the mental health market, similar to how novel approaches revolutionized other sectors.
Bear Case
- The biotech sector is notoriously volatile, and Enveric is no exception, with community sentiment fluctuating wildly based on news cycles.
- There's concern about the company's cash burn rate and potential need for further dilution, a common worry in development-stage biotechs.
- Some community members are skeptical about the efficacy and regulatory pathway for cannabinoid-based therapies, drawing parallels to other hyped but ultimately unsuccessful ventures.
- Despite the buzz, tangible results from clinical trials are still pending, creating uncertainty about the company's ability to deliver on its promises.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ENVB Latest News
-
Enveric Biosciences Announces Participation in 2026 BIO International Convention
gurufocus.com · Jun 16, 2026
-
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
businesswire.com · Jun 9, 2026
-
Enveric Biosciences Begins Genotoxicity Testing for EB-003
MT Newswires · Jun 2, 2026
-
Enveric Biosciences Initiates Investigational New Drug-enabling Genotoxicity Studies Of EB-003
benzinga · Jun 2, 2026
ENVB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENVB.
Price Targets
Wall Street price target analysis for ENVB.
ENVB MoonshotScore
What does this score mean?
The MoonshotScore rates ENVB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
Enveric Biosciences Begins Genotoxicity Testing for EB-003
Enveric Biosciences Initiates Investigational New Drug-enabling Genotoxicity Studies Of EB-003
Leadership: Joseph Edward Tucker
CEO
Joseph Edward Tucker serves as the CEO of Enveric Biosciences, Inc. He is responsible for managing the company's overall strategy and operations, overseeing a team of 5 employees. Tucker brings experience in the pharmaceutical and biotechnology industries. His background includes roles in corporate development, finance, and operations. He is focused on advancing Enveric's pipeline of cannabinoid-based therapeutics and building strategic partnerships to drive growth.
Track Record: Under Joseph Edward Tucker's leadership, Enveric Biosciences has focused on advancing its pipeline of cannabinoid-based therapeutics. Key milestones include the development of EV104 for osteoarthritis and EVM-101 and EVM-201 for cancer-related distress. Tucker has also focused on securing funding and building strategic partnerships to support the company's growth. His tenure has been marked by a focus on innovation and strategic execution.
What Investors Ask About Enveric Biosciences, Inc. (ENVB) — Healthcare
What does Enveric Biosciences, Inc. do?
Enveric Biosciences, Inc. is a pharmaceutical company focused on developing cannabinoid-based medicines for cancer care and related conditions. The company's pipeline includes a range of drug candidates targeting osteoarthritis, cancer-related distress, mental health indications, and topical skin applications. Enveric aims to create innovative therapies that address unmet needs in these areas by leveraging the therapeutic potential of cannabinoids. The company is focused on rigorous research and development to advance its products through clinical trials and regulatory approval, with the goal of establishing itself as a leader in the cannabinoid-based pharmaceutical space.
What are the main risks for ENVB?
Enveric Biosciences faces several key risks inherent to the biotechnology industry. These include the uncertainty of clinical trial outcomes, regulatory hurdles, and competition from established pharmaceutical companies. The company's reliance on external funding also poses a risk, as it may need to raise additional capital through equity or debt offerings, potentially diluting shareholder value. Furthermore, negative perceptions of cannabinoid-based therapies could hinder market acceptance and commercial success. Investors should carefully consider these risks when evaluating Enveric Biosciences.
What are the key factors to evaluate for ENVB?
Enveric Biosciences, Inc. (ENVB) holds an AI score of 31/100 (low). Not financial advice.
How frequently does ENVB data refresh on this page?
ENVB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ENVB's recent stock price performance?
Enveric Biosciences, Inc. (ENVB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary cannabinoid-based drug development platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ENVB overvalued or undervalued right now?
Valuing Enveric Biosciences, Inc. (ENVB) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ENVB?
Before investing in Enveric Biosciences, Inc. (ENVB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ENVB to a portfolio?
Key strength of Enveric Biosciences, Inc. (ENVB): Proprietary cannabinoid-based drug development platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.